Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer [Yahoo! Finance]
CalciMedica, Inc. (CALC)
Company Research
Source: Yahoo! Finance
DEDHAM, Mass., March 10, 2026 BUSINESS WIRE )--Qlaris Bio, Inc. ("Qlaris"), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company's Board of Directors. Dr. Guerard brings more than two decades of global leadership experience in ophthalmology and biotechnology, with a track record of advancing innovative therapies through late-stage development and toward commercialization. He succeeds Thurein Htoo, who played a pivotal role in establishing the company and advancing its clinical pipeline through key development milestones. Mr. Htoo will remain with the company through April 1, 2026, to support a seamless leadership transition. "As Qlaris advances QLS-111 into Phase 3 clinical development, we are pleased to welcome Fred as our next chief executive officer," said Ron Hunt, chairman of th
Show less
Read more
Impact Snapshot
Event Time:
CALC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALC alerts
High impacting CalciMedica, Inc. news events
Weekly update
A roundup of the hottest topics
CALC
News
- CalciMedica (CALC) had its price target lowered by Oppenheimer Holdings, Inc. from $20.00 to $10.00. They now have an "outperform" rating on the stock.MarketBeat
- CalciMedica Reports 2025 Financial Results and Provides Clinical UpdatesPR Newswire
- CalciMedica (NASDAQ:CALC) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- CalciMedica (NASDAQ:CALC) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CALC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
CALC
Sec Filings
- 3/12/26 - Form EFFECT
- 3/3/26 - Form S-3
- 3/3/26 - Form 10-K
- CALC's page on the SEC website